David Henry MD
Vice Chair, Department of Medicine; Clinical Professor of Medicine (Hematology-Oncology), Pennsylvania Hospital, Philadelphia, PennsylvaniaDr. David Henry is Vice Chair of the Department of Medicine and Clinical Professor of Hematology-Oncology at Pennsylvania Hospital in Philadelphia.
Dr. Henry was awarded his medical degree from the University of Pennsylvania School of Medicine, where he also completed resident and fellowship training.
In addition to his clinical responsibilities, Dr. Henry is a member of the American Board of Internal Medicine’s Subspecialty SEP Board of Hematology and a principal investigator for the Eastern Cooperative Oncology Group, Accelerated Community Oncology Research Network, and International Oncology Network research groups. His main interests for publication and research are anemia and neutropenia in oncology.
He is the Editor-in-Chief of MDEDGE.com/hematology-oncology and a reviewer for The New England Journal of Medicine, Journal of Clinical Oncology, Archives of Internal Medicine, and The Oncologist. He is also the author of a weekly podcast titled Blood and Cancer on iTunes.
Dr. Henry is a past winner of the annual Blockley-Osler Award for teaching at the University of Pennsylvania School of Medicine and is the director of the University of Vienna medical student exchange program in Philadelphia.
Recent Contributions to PracticeUpdate:
- Neoadjuvant Chemoradiation for Treatment of LARC
- Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC
- ASCO 2023: Abstract Recommendations From Dr. David Henry
- 2022 Top Story in Oncology: Durvalumab Plus Gemcitabine and Cisplatin as First-Line Treatment for Advanced Biliary Tract Cancer
- ESMO 2022: Recommendations From Dr. David Henry for General Oncology
- ASCO 2022: Abstract Recommendations From Dr. David Henry for Oncology
- Quantitative Nodal Burden and Mortality Across Solid Cancers
- 2021 Top Story in Oncology: Surgically Preventing HPV-Related Anal Cancer in HIV-Infected Individuals
- VITTP and TTP From COVID Vaccinations and/or Infection
- PD-L1b Inhibitors for Nsq-NSCLC